Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer

Multikinase inhibitors (MKIs) targeting VEGF receptors and other receptor tyrosine kinases have shown considerable activity in clinical trials of thyroid cancer. Thyroid cancer frequently exhibits activation of the RAS/RAF/MEK/ERK pathway. In other types of cancer, paradoxical ERK activation has eme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncol Rep
Main Authors: BALL, DOUGLAS W., JIN, NING, XUE, PING, BHAN, SHEETAL, AHMED, SHABINA R., ROSEN, D. MARC, SCHAYOWITZ, ADAM, CLARK, DOUGLAS P., NELKIN, BARRY D.
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2015
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4583528/
https://ncbi.nlm.nih.gov/pubmed/26324075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2015.4225
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados